AlphAIAlphAI — Financial news for AI agents
quiverquant.com$MCK

MCKESSON ($MCK) Releases Q2 2027 Earnings

McKesson ($MCK) reported Q2 2027 earnings of $11.68 per share, exceeding estimates by $0.87, but revenue of $110.96B missed expectations by $17.08M. Insiders sold shares, while hedge funds had mixed activity. Analysts' price targets range from $812 to $945.

Original reporting
quiverquant.com
Published Nov 4, 2026, 10:56 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 11:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
MCKESSON ($MCK) Releases Q2 2027 Earnings — source image
Source · quiverquant.com
Decision brief

The 30-second read

$MCKNeutralHigh
01

Why it matters

The mixed earnings results could trigger short‑term volatility, with the revenue shortfall likely outweighing the EPS beat in price action.

02

Market read

First‑report earnings for a large‑cap healthcare distributor; provides fresh data for traders.

03

What to watch

Strong cash flow from earnings beat and potential cost‑cutting measures may offset revenue concerns.

Relevance 8/10Novelty 8/10Timing: after market close

Background

McKesson Corp. (MCK) released its Q2 2027 earnings, reporting an EPS beat and a slight revenue miss.

Company-level read

Ticker impact

$MCKNeutralHigh confidence
Context

Q2 2027 earnings beat EPS estimate ($11.68 vs $10.81) but missed revenue ($110.96B vs $110.97B).

Expected impact

likely modest downside as investors weigh revenue miss against EPS beat

Evidence & confidence

Large‑cap earnings release with mixed results typically leads to short‑term price adjustment; the revenue shortfall is a negative catalyst despite the EPS beat.

Market effects

Sector

Healthcare distribution sector may see slight pressure as McKesson's revenue miss signals demand softness.

Regional

U.S. markets may see a minor dip in healthcare stocks post‑earnings.

Global

Limited; impact confined to U.S. listed healthcare distributors.

Counterpoint

What could challenge this read

Investors could view the revenue miss as a temporary issue and buy on the dip.

Key entities

  • Company
    McKesson Corp.

    U.S. healthcare services and distribution company.

Read at source← All news

StoryMcKesson posts strong Q2 FY2027 results, raises FY2027 EPS guidance and completes Precision Medicine Group acquisition

Also covered by

5 outlets

Related articles

$MCKHighAI 8/10

McKesson (MCK) Q2 2027 Earnings Call Transcript

McKesson (MCK) reported Q2 2027 earnings, highlighting investments in employee programs and strategic acquisitions. The company acquired Precision Medicine Group to advance its oncology and biopharma services, and plans to invest in Option Care Health. McKesson also extended its distribution agreement with CVS Health. The company reported strong market trends and growth across its platforms, with a focus on technology and automation to enhance services.

finance.yahoo.com
$MCKHighAI 9/10

Key facts: FY27 Outlook Raised; Deals Expanded; PMG Buy, Segment Split

McKesson (MCK) reported Q2 revenue of $110.96B (+8% YoY) and adjusted EPS of $11.68, beating estimates. It raised fiscal 2027 adjusted EPS guidance to $45.60–$46.40. The company extended a drug distribution deal with CVS Health and plans to buy 49% of Option Care Health for $1.4B. McKesson also completed its acquisition of Precision Medicine Group and announced plans to separate its medical-surgical solutions segment.

tradingview.com
$MCKHighAI 9/10

McKesson Corp (MCK) (Q2 2027) Earnings Call Highlights: Raised Guidance, GLP-1 Momentum

McKesson Corp (MCK) raised fiscal 2027 adjusted EPS guidance to $45.60-$46.40, citing 8% revenue growth to $111 billion in Q2. The company acquired Precision Medicine Group for $2.25 billion, extending oncology capabilities. Challenges include lower branded pharmaceutical pricing and medical-surgical segment profit decline. Management discussed strategic investments and long-term growth targets.

finance.yahoo.com
$MCKMedAI 8/10

McKesson Q2 Revenue Rises to $110.96B, EPS $10.44; $221M Restructuring Charge

McKesson reported fiscal Q2 2027 revenue of $110.96B, up from $103.15B a year earlier, with net income of $1.22B and EPS of $10.44. The company recorded $221M in restructuring charges for the six-month period. Gross profit rose to $3.96B, while operating income increased to $1.60B. Share buybacks reduced the weighted-average diluted shares, supporting per-share results. The company faces risks related to opiate litigation and rising interest expenses.

minichart.com.sg
$MCKHighAI 8/10

[McKesson Q2 2027 Earnings Call] McKesson Raises FY2027 EPS Guidance to $45.60-$46.40, Beats on 8% Revenue Growth and 26% GLP-1 Surge

McKesson (MCK) raised its FY2027 EPS guidance to $45.60-$46.40, up from $44.20-$45.00, citing 8% revenue growth and a 26% surge in GLP-1 medication sales. Q2 revenue was $111.0B, up 8%, with adjusted EPS at $11.68, up 18%. The company completed a $2.25B acquisition and plans a $1.4B investment. Management expects 6-10% revenue growth and 12-16% operating profit growth for FY2027.

finance.biggo.com